Department of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
Department of Epidemiology, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.
J Allergy Clin Immunol Pract. 2022 Aug;10(8):2093-2098. doi: 10.1016/j.jaip.2022.03.024. Epub 2022 Apr 8.
Overuse of oral corticosteroids (OCS) is associated with serious adverse effects. It is currently unknown what proportion of patients with asthma regularly use these drugs, or whether they are optimally treated by specialists to minimize the use of these drugs.
To investigate (1) the prevalence of patients requiring ≥2 courses or maintenance use of OCS (ie, frequent users), (2) their use of inhaled corticosteroids, and (3) who prescribed their asthma medications.
We analyzed OCS prescription data (Dutch IQVIA Prescription Database) focusing on adult patients receiving asthma medication between March 2017 and March 2018 (focus year). An OCS course was defined as ≥20 mg prednisolone equivalent for 3 to 28 days; maintenance OCS as 2.5 to 17.5 mg/day for >28 days. Prescribers were classified as specialist or general practitioners.
Of 182,849 adults taking asthma medications, 77.8% had not received a prescription for OCS and 7.2% of patients were frequent OCS users: 2.6% received ≥2 OCS courses and 4.6% were on maintenance OCS. Of the frequent OCS users, 45.8% received only low or medium doses (<500 μg/day) of inhaled corticosteroids. Within the preceding 3 years (2014-2017), 51.1% and 34.3% of patients prescribed ≥2 OCS courses or maintenance OCS, respectively, had received prescriptions from a general practitioner without medication adjustments by a specialist.
This prescription-fill study shows that 7.2% of Dutch patients with asthma were overexposed to OCS, of whom only about half used adequate doses of inhaled corticosteroids, and 40.3% had not received specialist intervention within the previous 3 years. This suggests that OCS overuse is often underdiagnosed and inadequately addressed.
过度使用口服皮质类固醇(OCS)会引起严重的不良反应。目前尚不清楚有多少哮喘患者经常使用这些药物,或者他们是否得到了专家的最佳治疗,以尽量减少这些药物的使用。
调查(1)需要≥2个疗程或维持使用 OCS(即频繁使用者)的患者比例,(2)他们使用吸入皮质类固醇的情况,以及(3)谁为他们开具哮喘药物。
我们分析了 OCS 处方数据(荷兰 IQVIA 处方数据库),重点关注 2017 年 3 月至 2018 年 3 月(重点年份)期间接受哮喘药物治疗的成年患者。OCS 疗程定义为≥20mg 泼尼松龙等效物,使用 3 至 28 天;维持 OCS 定义为每天 2.5 至 17.5mg,使用>28 天。开处方者分为专科医生和全科医生。
在 182849 名服用哮喘药物的成年人中,77.8%未接受 OCS 处方,7.2%的患者为频繁使用 OCS 者:2.6%接受了≥2 个 OCS 疗程,4.6%正在接受维持 OCS 治疗。在频繁使用 OCS 的患者中,45.8%仅接受低或中剂量(<500μg/天)的吸入皮质类固醇。在过去 3 年(2014-2017 年)中,分别有 51.1%和 34.3%的患者被处方了≥2 个 OCS 疗程或维持 OCS,但未接受专家进行药物调整。
这项处方研究表明,7.2%的荷兰哮喘患者过度暴露于 OCS,其中只有约一半患者使用了足够剂量的吸入皮质类固醇,并且 40.3%的患者在过去 3 年内未接受过专家干预。这表明 OCS 过度使用通常被漏诊,并且处理不当。